Athira Pharma to Participate in Upcoming May Conferences

Athira Pharma to Participate in Upcoming May Conferences

 

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May.

 

  Sidoti May 2024 Virtual Investor Conference  
Format: Company Presentation
Date and Time: Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET
Location: Virtual

 

  The Citizens JMP Life Sciences Conference  
Format: Fireside Chat
Date and Time: Monday, May 13, 2024, from 1:30 p.m. - 1:55 p.m. ET
Location: New York Hilton Midtown

 

Live webcasts of the panel and presentations can be accessed from the Investors section of the Athira website at   https://investors.athira.com/news-and-events/events-and-presentations-investor   . An archived replay of the webcasts will be available for at least 30 days following the event.

 

  About Athira Pharma, Inc.  
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates that modulate the neurotrophic HGF system, including fosgonimeton, which is being evaluated for the potential treatment of mild-to-moderate Alzheimer's disease in the Phase 2/3 LIFT-AD trial that is expected to report topline data in the second half of 2024. For more information, visit   www.athira.com   . You can also follow Athira on   Facebook   ,   LinkedIn   and @athirapharma on   X   , (formerly known as   Twitter    ) , and   Instagram   .

 

  Investor Contacts:  
Julie Rathbun
Athira Pharma
  Julie.rathbun@athira.com   
206-769-9219

 

Anne Marie Fields
Stern Investor Relations
  annemarie.fields@sternir.com   
332-213-1956

 

  Media Contact:  
Janine Bogris
Inizio Evoke Comms
  Janine.bogris@inizioevoke.com   
201-245-6838

 

  Primary Logo 

 

News Provided by GlobeNewswire via QuoteMedia

ATHA
The Conversation (0)
Stallion Uranium Enters into Technology Data Acquisition Agreement

Stallion Uranium Enters into Technology Data Acquisition Agreement

 

Stallion Uranium Corp. (the " Company " or " Stallion " ) ( TSX-V: STUD ; OTCQB: STLNF ; FSE: FE0 ) is pleased to announce that, it has entered into a technology data acquisition agreement (the " Agreement ") dated April 24 th 2025, amongst the Company and Matthew J. Mason (the " Lessor ") to enhance exploration efforts across its expansive uranium land package in the Athabasca Basin, Saskatchewan. The Lessor holds the exclusive license to certain proprietary technology and know how that can be used to assist in area prioritization selection for the purposes of exploration for minerals (the " Technology " or " Haystack ").

 

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Athena Gold

Athena Gold Closes Private Placement

Athena Gold Corporation (CSE: ATHA) (OTCQB: AHNRF) ("Athena Gold" or the "Company") is pleased to announce the closing of a non-brokered private placement previously announced on April 21, 2025 (the "Offering"). The Company has issued 3,322,000 units (the "Units") at a price of CAD $0.05 per Unit for gross proceeds of CAD $166,100.

Each Unit consists of one common share in the capital of the Company (a "Common Share") and one-half of a common share purchase warrant (a "Warrant"). Each whole Warrant is exercisable into one Common Share at a price of CAD $0.12 per Warrant for a period of thirty-six months from the date of issuance, subject to the following acceleration provision. If, at any time after the date that is 4 months and one day after the date of issuance of the Warrants, the average volume weighted trading price of the Company's Common Shares on the Canadian Securities Exchange (or such other stock exchange on which the Common Shares may be traded from time to time) is at or above CAD $0.20 per share for a period of 10 consecutive trading days (the "Triggering Event"), the Company may at any time, after the Triggering Event, accelerate the expiry date of the Warrants by giving ten calendar days notice to the holders of the Warrants, by way of news release, and in such case the Warrants will expire on the first day that is 30 calendar days after the date on which such notice is given by the Company announcing the Triggering Event.

Keep reading...Show less
Athena Gold

Athena Gold Provides Option on Excelsior Springs and Kicks off 2025 Field Season at Laird Lake

Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena Gold" or the "Company") is pleased to announce that it has entered into a property option agreement (the "Agreement") with Firetail Resources Limited (ASX:FTL) ("Firetail") dated May 28, 2025, whereby the Company has granted Firetail the exclusive right (the "Option") to acquire an 80% undivided interest in the Company's Excelsior Springs Project located in Nevada, USA ("Excelsior" or the "Property"). If the Option is exercised, Firetail will pay Athena Gold AUD$200,000 in cash and issue 32,000,000 ordinary shares, and Firetail will be required to incur USD$5,000,000 in expenditures over a five-year term. A 1% net smelter return royalty will also be provided to Athena Gold on certain claims comprising the Property. If Firetail successfully earns its 80% interest, the parties will form a joint venture partnership that provides Athena Gold with a 20% free-carried interest until a Definitive Feasibility Study is published.

Keep reading...Show less
Athena Gold

Athena Gold Extends Closing of Private Placement

Athena Gold Corporation (CSE:ATHA) (OTCQB:AHNRF) ("Athena Gold" or the "Company") ") announces that further to its news release of April 21, 2025, the Company has received approval from the Canadian Securities Exchange to extend closing of its $0.05 non-flow-through unit private placement for gross proceeds of up to $200,000 (the "NFT Offering") to July 5, 2025. There are no changes to the terms of the NFT Offering in connection with the extension. Further details regarding the NFT Offering can be found in the Company's news release dated April 21, 2025, which is available under the Company's SEDAR+ profile at www.sedarplus.ca.

Keep reading...Show less
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less
Zoono Group

Exclusive UK Packaging Agreement signed between Sharpak Aylesham Limited, Zoono, and OSY

Zoono Group Limited (Company) (ASX: ZNO) is pleased to update the market on an exclusive contract signed with Sharpak Aylesham Limited (Sharpak) and the Company’s partner in the food supply chain sector, OSY Group Limited (OSY).

Keep reading...Show less

Latest Press Releases

Related News

×